Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V® everolimus-eluting stents: One-year results from the XIENCE v USA study

Catheterization and Cardiovascular Interventions

Volumn 82, Issue 4, 2013, Pages

  Sudhir, Krishnankutty ^a,b   Hermiller, James B ^c   Naidu, Srihari S ^d   Henry, Timothy D ^e   Mao, Vivian W ^b   Zhao, Weiying ^b   Ferguson, Joanne M ^b   Wang, Jin ^b   Jonnavithula, Lalitha ^b   Simonton, Charles A ^b   Rutledge, David R ^b   Krucoff, Mitchell W ^f  

^a STANFORD UNIVERSITY   (United States)

^b ABBOTT VASCULAR   (United States)

^c Care Group   (United States)

^d WINTHROP UNIVERSITY HOSPITAL   (United States)

^e ABBOTT NORTHWESTERN HOSPITAL   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

drug eluting stent; everolimus; major adverse cardiac events; stent

Indexed keywords

EVEROLIMUS;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DRUG ELUTING STENT; EVEROLIMUS ELUTING STENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; QUALITY OF LIFE; REVASCULARIZATION; SAFETY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TARGET LESION FAILURE; TARGET LESION REVASCULARIZATION; TREATMENT FAILURE; WORLD HEALTH ORGANIZATION;

DRUG ELUTING STENT; EVEROLIMUS; MAJOR ADVERSE CARDIAC EVENTS; STENT;

AGED; CARDIOVASCULAR AGENTS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84879023723     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24749     Document Type: Article

References (34)

1. Serruys PW, Ruygrok P, Neuzner J, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: The SPIRIT II trial. EuroIntervention 2006; 2: 286-294.
2. Garg S, Serruys P, Onuma Y, et al. on behalf of the SPIRIT II Investigators. Three-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesion. The SPIRIT II trial. J Am Coll Cardiol Intv 2009; 2: 1190-1198.
3. Stone GW, Midei M, Newman W, et al.; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: A randomized trial. JAMA 2008; 299: 1903-1913.
4. Stone GW, Midei M, Newman W, et al. SPIRIT III Investigators. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical evaluation of the Xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial. Circulation 2009; 119: 680-686.
5. Nikolsky E, Lansky AJ, Sudhir K, et al. SPIRIT IV trial design: A large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Am Heart J 2009; 158: 520-526.
6. Stone GW, Rizvi A, Newman W, et al., for the SPIRIT IV investigators. A randomized clinical evaluation of everolimus-eluting and paclitaxel-eluting stents in patients with coronary artery disease. N Engl J Med. 2010; 362: 1663-1674.
7. Krucoff MW, Rutledge DR, Gruberg L, et al. A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus eluting coronary stent system condition-of-approval post-market study). JACC Cardiovasc Interv. 2011; 4: 1298-1309.
8. ACC/AHA guidelines for the management of patients with ST elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54: 2205-2241.
9. Garg S, Serruys PW,. Coronary stents. Current status. J Am Coll Cardiol 2010; 56 (Suppl S): S1-S42.
10. Stone GW, Witzenbichler B, Guagliumi G, et al.; HORIZONS-AMI Trial Investigators. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): Final 3-year results from a multicentre, randomised controlled trial. Lancet 2011; 377: 2193-2204.
11. Kedhi E, Gomes M, Joesoef SK, et al.; The COMPARE investigators. Everolimus-eluting stents and paclitaxel-eluting stents in patients presenting with myocardial infarction: Insights from the two year results of the COMPARE prospective randomized controlled trial. EuroIntervention 2012; 7: 1376-1385.
12. Cutlip DE, Windecker S, Mehran R, et al.; Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation. 2007; 115: 2344-2351.
13. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007; 116: 2634-2653.
14. Vranckx P, Cutlip DE, Mehran R, et al. Myocardial infarction adjudication in contemporary all-comer stent trials: Balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. EuroIntervention 2010; 5: 871-874.
15. Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina Questionnaire: A new functional status measure for coronary artery disease. J Am Coll Cardiol 1995; 25: 333-341.
16. Rutledge DR, Hermiller JB, Mao VW, Wang J, Krucoff MW,. Impact of everolimus-eluting stent on health status of standard-risk and extended-risk patients: One-year results from the XIENCE V USA study. Quality Life Res, in press.
17. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention - summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention). Circulation 2006; 113: 156-175.
18. King SB, Smitch SC Jr, Jacobs AK, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008; 51: 172-209.
19. Daemen J, van Twisk PH, Kukreja N, et al. The relative safety and efficacy of bare-metal and drug-eluting stents in low and high-risk patient subsets. An epidemiological analysis of three sequential cohorts of consecutive all comers (n = 6129). EuroIntervention 2009; 4: 464-474.
20. Applegate RJ, Sacrinty MT, Kutcher MA, et al. "Off-label" stent therapy 2-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2008; 51: 607-614.
21. Smits PC, Kedhi E, Royaards KJ, et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: A randomized open label trial). J Am Coll Cardiol 2011; 58: 11-18.
22. Stone GW, Maehara A, Lansky AJ, et al. PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011; 364: 226-235.
23. Kukreja N, Onuma Y, Garcia-Garcia HM, et al. Primary percutaneous coronary intervention for acute myocardial infarction: long-term outcome after bare metal and drug-eluting stent implantation. Circ Cardiovasc Interv 2008; 1: 103-110.
24. Vink MA, Dirksen MT, Suttorp MJ, Tijssen JG, van Etten J, Patterson MS, Slagboom T, Kiemeneij F, Laarman GJ,. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. JACC Cardiovasc Interv 2011; 4: 24-29.
25. Spaulding C, Teiger E, Commeau P, et al. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). JACC Cardiovasc Interv 2011; 4: 14-23.
26. Di Lorenzo E, Sauro R, Varricchio A, et al. Benefits of drug-eluting stents as compared with bare metal stent in ST-segment elevation myocardial infarction: 4 year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J 2009; 158: e43-e50.
27. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005; 293: 2109-2117
28. Sabate M, Cequier A, Iñiguez A, et al. ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet. Published online September 3, 2012 http://dx.doi.org/10.1016/ S0140-6736(12)61223-9.
29. Petersen RJ, Rozelle LT,. Ethylcellulose perfluorobutyrate: A highly non-thrombogenic fluoropolymer for gas exchange membranes. Trans Am Soc Artif Intern Organs 1975; 21: 242-248.
30. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis. Lancet 2012; 379: 1393-1402.
31. Spertus JA, Winder JA, Dewhurst TA, et al. Monitoring the quality of life in patients with coronary artery disease. Am J Cardiol 1994; 74: 1240-1244.
32. Spertus J, Safley D, Garg M, et al. The influence of race on health status outcomes one year after an acute coronary syndrome. J Am College Cardiol 2005; 46: 1838-1844.
33. Rahimi AR, Spertus JA, Reid KJ, et al. Financial barriers to health care and outcomes after acute myocardial infarction. JAMA 2007; 297: 1063-1072.
34. De Bruyne B, Pijls NH, Kalesan B, et al.; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 2012; 367: 991-1001. Epub 2012 Aug 27.